Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous human T-lymphocytes that have been genetically modified to express the CAR construct Hu1928-Hu20BB that consists of two chimeric antigen receptor (CAR) constructs: one encoding a fully-human anti-CD19 CAR with a co-stimulatory domain of CD28, Hu19-CD828, and one encoding a human anti-CD20 CAR with a co-stimulatory domain of 4-1BB (CD137), Hu20BB, with potential immunostimulating and antineoplastic activities. Upon re-infusion, the anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T-lymphocytes Hu1928-Hu20BB recognize and kill CD19- and/or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- and/or CD20-expressing tumor cells, thereby causing tumor cell lysis. Both the tumor-associated antigens (TAAs) CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.

**Synonyms:** - Autologous CAR-19/CAR-20-T Cells Hu1928-Hu20BB - Hu1928-Hu20BB - nti-CD19/CD20 CAR Autologous T-lymphocytes Hu1928-Hu20BB